Literature DB >> 8869282

Clinico-pathological features and p53 expression in left-sided sporadic colorectal cancers with and without microsatellite instability.

M Ilyas1, I P Tomlinson, M R Novelli, A Hanby, W F Bodmer, I C Talbot.   

Abstract

Defects in mismatch repair (MMR) can result in the development of a 'mutator phenotype', manifest as an increase in DNA replication errors (RERs). Patients with hereditary non-polyposis colorectal cancer (HNPCC) have germline mutations in MMR genes. These patients develop carcinomas of the colon and other specific sites at a significantly earlier age than patients with sporadic carcinomas. RERs are found in the cancers from patients with HNPCC and have been demonstrated in 10-20 per cent of sporadic colorectal cancers (CRCs). Loss of MMR may simply accelerate tumour development, but it is also possible that these tumours follow a different carcinogenetic pathway from tumours with intact MMR. In particular, it has been suggested that p53 mutations occur less often in RER-positive (RER+) sporadic colorectal cancers. In this study, the clinico-pathological features and frequency of p53 overexpression in 17 left-sided RER+ CRCs were compared with 35 left-sided RER- CRCs. No differences were found in the age and tumour stage at presentation, mucinous differentiation, or Jass prognostic grouping between these two types of CRC. Thirteen out of 17 (76 per cent) RER+ and 19/35 (54 per cent) RER- tumours showed overexpression of p53, a non-significant difference (chi 2 test). Although some previous studies have suggested differences in the clinico-pathological features and p53 expression of RER+ and RER- right-sided CRCs, our results show that these differences do not exist in left-sided cancers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8869282     DOI: 10.1002/(SICI)1096-9896(199608)179:4<370::AID-PATH627>3.0.CO;2-N

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Allele loss, replication errors and loss of expression of E-cadherin in colorectal cancers.

Authors:  M Ilyas; I P Tomlinson; A Hanby; I C Talbot; W F Bodmer
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

2.  Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer.

Authors:  B Curran; K Lenehan; H Mulcahy; O Tighe; M A Bennett; E W Kay; D P O'Donoghue; M Leader; D T Croke
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

Review 3.  What we could do now: molecular pathology of colorectal cancer.

Authors:  R S Houlston
Journal:  Mol Pathol       Date:  2001-08

Review 4.  The links between axin and carcinogenesis.

Authors:  S Salahshor; J R Woodgett
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 5.  Genetic prognostic markers in colorectal cancer.

Authors:  R S Houlston; I P Tomlinson
Journal:  Mol Pathol       Date:  1997-12

Review 6.  [Clinical, pathological and molecular prognostic factors in colorectal carcinomas].

Authors:  S E Baldus
Journal:  Pathologe       Date:  2003-01-21       Impact factor: 1.011

7.  Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences.

Authors:  T Fujiwara; J M Stolker; T Watanabe; A Rashid; P Longo; J R Eshleman; S Booker; H T Lynch; J R Jass; J S Green; H Kim; J Jen; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

8.  Morphology of sporadic colorectal cancer with DNA replication errors.

Authors:  J R Jass; K A Do; L A Simms; H Iino; C Wynter; S P Pillay; J Searle; G Radford-Smith; J Young; B Leggett
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

9.  Activity (transcription) of the genes for MLH1, MSH2 and p53 in sporadic colorectal tumours with micro-satellite instability.

Authors:  S I H Tou; E R Drye; P B Boulos; S J Hollingsworth
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.